查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球管道成形術治療市場 -2023-2030
市場調查報告書
商品編碼
1374785

全球管道成形術治療市場 -2023-2030

Global Canaloplasty Treatment Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

淚管成形術是一種用於治療青光眼的外科手術，青光眼是一組以眼內壓 (IOP) 升高為特徵的眼部疾病，可損害視神經並導致視力喪失。淚管成形術的主要目標是降低升高的眼壓，眼壓是青光眼視神經損傷和進行性視力喪失的主要危險因子。透過疏通和擴大眼睛的自然排水系統，管道成形術可以有效降低眼壓並幫助保護視力。

管道成形術帶來的持久眼壓降低可以幫助患者避免或推遲進一步的手術，並減少頻繁調整藥物的需要。對於各種個體，包括那些患有輕度至中度開角型青光眼、尚未通過藥物緩解並正在尋找手術選擇的患者，眼管成形術可能是一種有效的治療方法。想要減少與更具侵入性的手術相關的危險的患者也可以選擇它。

市場動態：促進因素與限制因素

公司採取的策略

該公司的產品發布和產品技術開發等策略加速了市場成長。例如，2022 年 4 月，Nova Eye Medical Limited 在一些歐洲和亞洲地區提供下一代管道成形術設備 iTrack Advance地區。 iTrack Advance 的推出表明了我們致力於擴大管道成形術領域的決心。該公司預計 iTrack Advance 的發布將導致白內障外科醫生和普通眼科醫生進行眼管成形術的數量增加。

推動全球血管成形術市場收入成長的主要因素之一是青光眼病例的增加。青光眼患者的數量呈現週期性增加，因為這種疾病是一種無痛眼部疾病，直到視力嚴重喪失時才會出現症狀。因此，上述因素推動了市場的成長。

市場動態：克制

管道成形術有許多積極作用，但也有一些因素可能阻礙其廣泛使用或限制其在特定情況下的應用。例如，管道成形術是一種敏感的治療方法，要求外科醫生具有高水準的能力和經驗。

並非所有眼外科醫生都熟練使用該技術，並且與許多其他複雜的手術治療一樣，該技術的成本可能很高，這可能限制了患者對眼管成形術的可用性。特別是在醫療保健覆蓋不足或患者必須自掏腰包進行醫療手術的地區或國家，費用可能是關鍵的影響因素。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按類型分類
  • 手術技術片段
  • 最終使用者的片段
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 青光眼疾病的興起
      • 公司採取的策略
  • 限制
      • 與治療相關的高費用
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按類型

  • 傳統管道成形術
  • 微導管輔助管道成形術

第 8 章：透過手術技術

  • 經內管成形術
  • 體外管道成形術

第 9 章：按最終用戶

  • 眼科診所
  • 醫院
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Nova Eye Medical Limited
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Ellex Medical Lasers
  • Haag-Streit
  • New World Medical
  • Sight Sciences
  • Glaukos Corporation
  • Ophthalmic Instruments Pte Ltd.
  • New World Medical, Inc
  • Ohio Eye Alliance
  • iScience Interventional

第 13 章：附錄

簡介目錄
Product Code: MD7193

Overview

Canaloplasty is a surgical procedure used to treat glaucoma, a group of eye conditions characterized by increased intraocular pressure (IOP) that can damage the optic nerve and lead to vision loss. The primary goal of canaloplasty is to lower elevated IOP, which is a major risk factor for optic nerve damage and progressive vision loss in glaucoma. By unblocking and widening the eye's natural drainage system, canaloplasty can effectively reduce IOP and help preserve vision.

Long-lasting IOP reduction from canaloplasty can help patients avoid or delay further procedures and lessen the need for frequent medication modifications. For a variety of individuals, including those with mild to moderate open-angle glaucoma who have not found relief from medication and are searching for a surgical option, canaloplasty may be an effective course of treatment. Patients who want to reduce the dangers connected with more invasive surgeries can additionally opt for it.

Market Dynamics: Drivers and Restraints

The strategies adopted by the companies

The strategies like product launches and technological developments of the products by the companies which accelerates the market growth.For instance, in April 2022, Nova Eye Medical Limited is offering the iTrack Advance, a next-generation canaloplasty device, in a few European and Asian regions. The launch of the iTrack Advance demonstrates our dedication to expanding the canaloplasty sector. The company anticipates that the release of iTrack Advance will lead to an increase in the number of cataract surgeons and general ophthalmologists performing canaloplasty procedures.

One of the main factors propelling the growth of the worldwide canaloplasty market's revenue is the rise in glaucoma cases. The number of glaucoma patients is cyclically increasing because the condition is a painless eye ailment that does not cause symptoms until there is considerable vision loss. Thus above factors boost the market growth.

Market Dynamics: Restraint

Canaloplasty has a number of positive effects but there are also certain things that can prevent it from being widely used or limit its application in specific circumstances. For instance, canaloplasty is a sensitive treatment that demands a surgeon to have a high level of competence and experience.

The availability of canaloplasty to patients may be constrained by the fact that not all eye surgeons are skilled in using this technique, and it can be costly, like many other sophisticated surgical treatments. Particularly in areas or nations with inadequate healthcare coverage or where patients must pay out-of-pocket for medical operations, the cost may be a crucial influencing factor.

Segment Analysis

The global canaloplasty treatment market is segmented based on type, surgical techniques, end-user and region.

The microcatheter-assisted canaloplasty segment from the type segment accounted for approximately 41.7% of canaloplasty treatment share

Microcatheter-assisted canaloplasty is a minimally invasive procedure. It avoids the need for major incisions and reduces trauma to the eye. This minimizes post-operative discomfort and promotes faster recovery compared to traditional, more invasive glaucoma surgeries. Ongoing advancements in microcatheter technology and surgical techniques continue to refine and improve the outcomes of microcatheter-assisted canaloplasty, making it an increasingly viable option for glaucoma patients.

Additionally, the novel products helps to accelerates the segment growth. For instance, in March 2021, Sight Sciences, Inc., a growth-stage Medical Device company focused on addressing the underlying causes of the world's most common eye conditions, the OMNI Surgical System (OMNI) had approved USFDA 510(k) clearance for canaloplasty (microcatheterization and transluminal vasodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce Intraocular Pressure (IOP). Thus above factors boost the segment growth.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share in 2022

North America is expected to account for the largest revenue share over the forecast period. Leading market players' presence, efficient reimbursement policies, and public health programs such as Eye America and rise of glaucoma helps to boost the region growth. For instance, according to CDC, a series of illnesses known as glaucoma harm the optic nerve in the eye, which can lead to vision loss and even blindness.

Glaucoma affects about 3 million Americans. It is the second most common cause of blindness in the globe. The most prevalent type of glaucoma, open-angle glaucoma, causes an increase in ocular pressure. Since glaucoma frequently has no early symptoms, 50% of those who have it are unaware that exist. Due to improvements in healthcare infrastructure, rising disposable income, the established presence of domestic companies in the region, the availability of glaucoma surgery devices, healthcare reforms, and technological advancements, Asia Pacific is predicted to experience significant revenue over the forecast period.

COVID-19 Impact Analysis

Restrictions and safety concerns initially limited patient access to treatment centers. Yet, as restrictions relaxed, there was a noticeable market recovery, emphasizing minimally invasive procedures and a rise in telemedicine consultations. Manufacturers and healthcare providers adjusted to the new circumstances by enforcing rigorous safety measures. The market's progress is steadily improving as healthcare systems stabilize and patient confidence rebounds. Future growth is fueled by innovation and a patient-focused approach.

Competitive Landscape

The major global players in the market include: Nova Eye Medical Limited, Ellex Medical Lasers, Haag-Streit, New World Medical, Sight Sciences, Glaukos Corporation, Ophthalmic Instruments Pte Ltd., New World Medical, Inc, Ohio Eye Alliance, iScience Interventional and among others.

Key Developments

  • In November 10, 2021, the Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) authorising the company to conduct a clinical study to evaluate the safety and effectiveness of a new, higher volume, investigational OMNI device ("higher volume OMNI") to perform canal viscodilation alone to lower intraocular pressure. Sight Sciences, Inc. is an eyecare technology company focused on developing innovative solutions intended to transform standards of care and improve patients' lives.

Why Purchase the Report?

  • To visualize the global canaloplasty treatment market segmentation based on type, surgical techniques, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of canaloplasty treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global canaloplasty treatment market report would provide approximately 61 tables, 63 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Surgical Techniques
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rise of glaucoma diseases
      • 4.1.1.2. The strategies adopted by the companies
  • 4.2. Restraints
      • 4.2.1.1. High cost associated with the treatment
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Traditional Canaloplasty *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Microcatheter-assisted Canaloplasty

8. By Surgical Techniques

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 8.1.2. Market Attractiveness Index, By Surgical Techniques
  • 8.2. Ab-interno canaloplasty *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ab-externo canaloplasty

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Ophthalmology clinics *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospitals
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgical Techniques
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Nova Eye Medical Limited *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Ellex Medical Lasers
  • 12.3. Haag-Streit
  • 12.4. New World Medical
  • 12.5. Sight Sciences
  • 12.6. Glaukos Corporation
  • 12.7. Ophthalmic Instruments Pte Ltd.
  • 12.8. New World Medical, Inc
  • 12.9. Ohio Eye Alliance
  • 12.10. iScience Interventional

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us